Patents by Inventor Michael Konkel

Michael Konkel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9047864
    Abstract: Methods and compositions for reducing the incidence of C. jejuni bacteria infections in poultry and in humans and other animals are formulated to include C. jejuni antigens, and particularly CadF, FlpA and FlaA. The antigens may be provided in the form of polypeptides or by hosts that produce the antigens. Fibronectin binding proteins of C. jejuni may also be used to deliver substances of interest to humans and other animals.
    Type: Grant
    Filed: July 16, 2010
    Date of Patent: June 2, 2015
    Assignee: Washington State University
    Inventors: Michael Konkel, Tri Duong, Charlie Larson, Jason Neal-McKinney
  • Publication number: 20120183570
    Abstract: Methods and compositions for reducing the incidence of C. jejuni bacteria infections in poultry and in humans and other animals are formulated to include C. jejuni antigens, and particularly CadF, FlpA and FlaA. The antigens may be provided in the form of polypeptides or by hosts that produce the antigens. Fibronectin binding proteins of C. jejuni may also be used to deliver substances of interest to humans and other animals.
    Type: Application
    Filed: July 16, 2010
    Publication date: July 19, 2012
    Inventors: Michael Konkel, Tri Duong, Charlie Larson, Jason Neal-McKinney
  • Patent number: 8198313
    Abstract: This invention is directed to indolone derivatives which are antagonists for the GALR3 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: January 10, 2011
    Date of Patent: June 12, 2012
    Assignee: H. Lundbeck A/S
    Inventors: Michael Konkel, John M. Werzel, Jamie Talisman
  • Publication number: 20110178125
    Abstract: This invention is directed to indolone derivatives which are antagonists for the GALR3 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier.
    Type: Application
    Filed: January 10, 2011
    Publication date: July 21, 2011
    Inventors: Michael Konkel, John M. Werzel, Jamie Talisman
  • Patent number: 7868034
    Abstract: This invention is directed to indolone derivatives which are antagonists or the GALR3 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: June 17, 2008
    Date of Patent: January 11, 2011
    Assignee: H. Lundbeck A/S
    Inventors: Michael Konkel, John M. Werzel, Jamie Talisman
  • Publication number: 20090176840
    Abstract: This invention is directed to indolone derivatives which are antagonists or the GALR3 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier.
    Type: Application
    Filed: June 17, 2008
    Publication date: July 9, 2009
    Inventors: Michael Konkel, John M. Werzel, Jamie Talisman
  • Publication number: 20070259942
    Abstract: This invention is directed to pyrimidine and indolone derivatives which are selective antagonists for the GAL3 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of a compound of the invention effective to treat the subject's depression and/or anxiety.
    Type: Application
    Filed: September 6, 2006
    Publication date: November 8, 2007
    Inventors: Thomas Blackburn, Michael Konkel, Lakmal Boteju, Ian Talisman, John Wetzel, Mathivanan Packiarajan, Heidi Chen, Hermo Jimenez
  • Publication number: 20070054910
    Abstract: This invention is directed to indolone derivatives which are antagonists for the GALR3 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier.
    Type: Application
    Filed: March 23, 2006
    Publication date: March 8, 2007
    Inventors: Michael Konkel, John Wetzel, Jamie Talisman
  • Patent number: 7166635
    Abstract: This invention is directed to indolone derivatives which are selective antagonists for the GalR3 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of a compound of the invention effective to treat the subject's depression and/or anxiety.
    Type: Grant
    Filed: February 28, 2005
    Date of Patent: January 23, 2007
    Assignee: H. Lundbeck A/S
    Inventors: Michael Konkel, John M. Wetzel, Jamie Talisman
  • Publication number: 20060172989
    Abstract: This invention is directed to aminoalkoxyphenyl indolone derivatives which are ligands at the GAL3 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by admixing a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of treating a subject suffering from depression and/ or anxiety which comprises administering to the subject an amount of a compound of the subject invention.
    Type: Application
    Filed: February 2, 2005
    Publication date: August 3, 2006
    Inventors: Michael Konkel, Mathivanan Packiarajan, Heidi Chen, Upendra Topiwala, Hermogenes Jimenez, Jamie Talisman
  • Publication number: 20060173192
    Abstract: This invention is directed to aminoalkylphenyl indolone derivatives which are ligands at the GAL3 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by admixing a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of a compound of the subject invention.
    Type: Application
    Filed: January 31, 2006
    Publication date: August 3, 2006
    Inventors: Michael Konkel, Mathivanan Packiarajan, Heidi Chen
  • Publication number: 20060173180
    Abstract: This invention is directed to aminoalkoxyphenyl indolone derivatives, which are ligands at the GAL3 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by admixing a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of a compound of the subject invention.
    Type: Application
    Filed: January 31, 2006
    Publication date: August 3, 2006
    Inventors: Michael Konkel, Mathivanan Packiarajan, Heidi Chen, Upendra Topiwala, Hermogenes Jimenez, Jamie Talisman
  • Patent number: 7081470
    Abstract: This invention is directed to indolone derivatives which are antagonists for the GALR3 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: April 16, 2003
    Date of Patent: July 25, 2006
    Assignee: H. Lundbeck A/S
    Inventors: Michael Konkel, John M. Werzel, Jamie Talisman
  • Publication number: 20050148635
    Abstract: This invention is directed to indolone derivatives which are selective antagonists for the GalR3 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of a compound of the invention effective to treat the subject's depression and/or anxiety.
    Type: Application
    Filed: February 28, 2005
    Publication date: July 7, 2005
    Inventors: Michael Konkel, John Wetzel, Jamie Talisman
  • Publication number: 20040106623
    Abstract: This invention is directed towards a method of inhibiting activation of a human &agr;1d adrenergic receptor which comprises contacting the receptor with a compound so as to inhibit activation of the receptor, wherein the compound binds selectively to a human &agr;1d adrenergic receptor. This invention provides for a compound which binds selectively to a human &agr;1d adrenergic receptor. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier. This invention further provides for a method of treating a subject afflicted with a disease which is susceptible to treatment by antagonism of the human &agr;1d adrenergic receptor which comprises administering to the subject an amount of the above defined compounds effective to treat the disease.
    Type: Application
    Filed: November 20, 2003
    Publication date: June 3, 2004
    Applicant: Synaptic Pharmaceutical Corporation
    Inventors: Michael Konkel, John M. Wetzel, Stewart A. Noble, Charles Gluchowski, Douglas A. Craig
  • Publication number: 20040102507
    Abstract: This invention is directed to indolone derivatives which are antagonists for the GALR3 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier.
    Type: Application
    Filed: April 16, 2003
    Publication date: May 27, 2004
    Inventors: Michael Konkel, John M. Werzel, Jamie Talisman
  • Publication number: 20040082615
    Abstract: This invention is directed to indolone derivatives which are selective antagonists for the GalR3 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of a compound of the invention effective to treat the subject's depression and/or anxiety.
    Type: Application
    Filed: August 7, 2003
    Publication date: April 29, 2004
    Inventors: Michael Konkel, John M. Wetzel, Jamie Talisman
  • Patent number: 6706716
    Abstract: This invention is directed towards a method of inhibiting activation of a human &agr;1d adrenergic receptor which comprises contacting the receptor with a compound so as to inhibit activation of the receptor, wherein the compound binds selectively to a human &agr;1d adrenergic receptor. This invention provides for a compound which binds selectively to a human &agr;1d adrenergic receptor. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier. This invention further provides for a method of treating a subject afflicted with a disease which is susceptible to treatment by antagonism of the human &agr;1d adrenergic receptor which comprises administering to the subject an amount of the above defined compounds effective to treat the disease.
    Type: Grant
    Filed: January 17, 2001
    Date of Patent: March 16, 2004
    Assignee: Synaptic Pharmaceutical Corporation
    Inventors: Michael Konkel, John M. Wetzel, Stewart A. Noble, Charles Gluchowski, Douglas A. Craig
  • Publication number: 20020028760
    Abstract: This invention is directed towards a method of inhibiting activation of a human &agr;1d adrenergic receptor which comprises contacting the receptor with a compound so as to inhibit activation of the receptor, wherein the compound binds selectively to a human ald adrenergic receptor. This invention provides for a compound which binds selectively to a human &agr;1d adrenergic receptor. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier. This invention further provides for a method of treating a subject afflicted with a disease which is susceptible to treatment by antagonism of the human &agr;1d adrenergic receptor which comprises administering to the subject an amount of the above defined compounds effective to treat the disease.
    Type: Application
    Filed: January 17, 2001
    Publication date: March 7, 2002
    Inventors: Michael Konkel, John M. Wetzel, Stewart A. Noble, Charles Gluchowski, Douglas A. Craig